Ibogaine draws Americans to Mexico for costly psychedelic retreats

Americans, including high-profile figures like CEOs and celebrities, are increasingly traveling to Mexico to undergo ibogaine treatment, according to a report by the New York Post. This psychoactive compound, derived from African plants, is gaining attention for its potential to treat substance use disorders, PTSD, and traumatic brain injuries. However, it is also attracting those seeking personal transformation, despite being a Schedule I controlled substance in the United States.

What the report found

The New York Post highlights that individuals such as Mike Stratton, co-founder of Marek Health, have turned to ibogaine for personal growth. Stratton described his experience as a challenging "hell ride" that ultimately led to a sense of peace. Similarly, Presley Gerber, son of Cindy Crawford, sought ibogaine treatment at Beōnd Ibogaine in Cancún, Mexico, to "rewire" his brain in the face of addiction.

Regulatory context

Ibogaine remains a Schedule I controlled substance in the U.S., meaning it is not approved for medical use. However, it is permitted in Mexico, making the country a destination for Americans seeking treatment. Clinics like Beōnd Ibogaine cater to a diverse clientele, including professionals, celebrities, and retirees, who are drawn by promises of "spiritual growth" and "peak performance."

Why it matters

The growing interest in ibogaine for personal growth underscores a broader trend of seeking alternative therapies outside traditional medical frameworks. While some report significant personal insights and improvements, experts caution that scientific evidence supporting these claims is still limited. Dr. Eduardo Ramirez, clinical director at Beōnd, notes that while research is ongoing, the most robust evidence currently supports ibogaine's use in addiction and trauma treatment.

The experience and integration

Participants in ibogaine retreats often undergo a "flood dose," which is intended to induce a full psychedelic experience. Stratton and others describe this as a deeply introspective process that can be both challenging and transformative. Post-treatment, clients engage in activities like meditation and group sessions to integrate their experiences into daily life.

Despite the potential benefits, experts like Talia Eisenberg, co-founder of Beōnd, emphasize that ibogaine is not a "silver bullet." The process requires a willingness to confront personal issues and integrate insights into one's life.

The rising interest in ibogaine highlights the ongoing exploration of psychedelics for personal and therapeutic purposes, even as regulatory challenges persist in the U.S.